November 20, 2026

US FDA approves Merck's drug for kidney cancer

The drug, branded as Welireg, is used to treat patients with renal cell carcinoma who have received prior treatment

US FDA approves Merck's drug for kidney cancer
Signage is seen outside of the Food and Drug Administration (FDA) headquarters in White Oak, Maryland, U.S., August 29, 2020. REUTERS/Andrew Kelly

Reuters

Published : 15 Dec 2023, 11:52 PM

Updated : 15 Dec 2023, 11:52 PM

The US Food and Drug Administration on Thursday approved Merck's (MRK.N) drug belzutifan for a type of kidney cancer.

The drug, branded as Welireg, is used to treat patients with renal cell carcinoma who have received prior treatment.

Renal cell carcinoma is a disease in which cancer cells are found in the lining of very small tubes in the kidney.

Welireg's approval is based on data from a late-stage trial, where the drug showed statistically significant and clinically meaningful improvement in progression-free survival (PFS) of patient compared to Novartis' (NOVN.S) drug, everolimus.

PFS refers to how long a patient lives without the disease getting worse after treatment.

In 2021, the drug was approved for cancers associated with Von Hippel-Lindau Disease, a rare, genetic disorder in which non-cancerous tumors grow in certain parts of the body.

Related Stories